Endo hopes to improve in all areas, forcing the company to make some hard decisions moving forward. Specifically, during his tenure, Par significantly increased total revenue, acquired JHP Pharmaceuticals and established a presence in the European generics market.
Advertisement
Currently, Campanelli serves as president of Endo’s generic and OTC drugs business, Par Pharmaceutical, which accounts for roughly 60% of Endo’s total revenues through the first half of 2016.
Shares of Endo International PLC (NASDAQ: ENDP) saw a handy gain in Friday’s session after the company announced a change in senior management.
Analysts argue that Campanelli’s appointment revealed the growing importance of Endo’s generics business. “Paul has spent a significant portion of his career leading and operating complex generics businesses and overseeing Par’s branded business”. The company reported $0.86 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.74 by $0.12.
Endo International PLC (NASDAQ:ENDP) updated its FY16 earnings guidance on Friday. TX now owns 126,880 shares of the company’s stock worth $1,978,000 after buying an additional 12,410 shares during the last quarter. The stock has a 50 day moving average price of $21.12 and a 200 day moving average price of $22.00. Deutsche Bank AG reaffirmed a buy rating and issued a $31.00 price target on shares of Endo International PLC in a report on Wednesday, June 15th. One analyst has rated the stock with a sell rating, eleven have assigned a hold rating and eleven have assigned a buy rating to the stock. Vetr lowered shares of Endo International PLC from a strong-buy rating to a buy rating and set a $19.14 price target on the stock.in a report on Thursday, July 7th.
“We’ve got a team, and they’re out there pursuing opportunities both on the brand and generic side”, said the new CEO on an investor’s call. Endo International PLC presently has an average rating of “Hold” and a consensus target price of $39.32. The U.S. Branded Pharmaceuticals offers products that focus on the treatment and management of conditions in urology, urologic oncology, endocrinology, and orthopedics.
Advertisement
ENDP also makes up 1.1% of the Market Vectors Generic Drugs ETF (NasdaqGM: GNRX), the only generics-focused US -listed ETF. The International Pharmaceuticals segment includes a variety of pharmaceutical products for the Canadian, Latin American, South African, and world markets.
